Page 77 - MI-2-3

Microbes & Immunity Natural phage patentability in the U.S.

Appendix

Table A1. Comparison of claims in the application and granted form of two patents
Patent Application form (20210228659-A1) Granted form (11779617-B2) Note
Patent 1 1. An antibacterial composition comprising 1. An antibacterial composition comprising at least one Canceled SEQ ID NO1; sequence
at least one bacteriophage having lytic bacteriophage having lytic activity against a P. aeruginosa identity requirement changed from
activity against a P. aeruginosa strain, strain and a pharmaceutically acceptable excipient or 90% to 99%
said at least one bacteriophage selected carrier, said at least one bacteriophage being selected
from the bacteriophages having a genome from the bacteriophages having a genome comprising
comprising a nucleotide sequence of any a nucleotide sequence of any one of SEQ ID NOs: 2 – 7
one of SEQ ID NOs: 1 – 7 or a sequence or a sequence having at least 99% identity thereto, and
having at least 90% identity thereto. 2 – 4. said pharmaceutically acceptable excipient or carrier
(canceled) comprising a preservative in an amount effective to
preserve the activity of the bacteriophage.
5. The composition of claim 1, comprising 2. The composition of claim 1, comprising at least one The phage names and sequences
at least one bacteriophage of Table 1. bacteriophage selected from the group consisting were specified
6. (canceled) of BP1777, BP1792, BP1797, BP1800, BP1902,
and BP1940, said bacteriophage having a genome
comprising the nucleotide sequence of SEQ ID NOs:
2 – 7, respectively.
7. The composition of claim 1, which is lytic 3. The composition of claim 1, which is lytic against Unchanged
against antibiotic-resistant P. aeruginosa antibiotic-resistant P. aeruginosa strains.
strains.
8. The composition of claim 1, which is lytic 4. The composition of claim 1, which is lytic against more Unchanged
against more than 90% of all bacterial than 90% of all bacterial strains of the LMG collection.
strains of the LMG collection.
9. The composition of claim 1, which 5. The composition of claim 1, wherein the Pharmaceutically acceptable
further comprises a pharmaceutically pharmaceutically acceptable excipient or carrier excipients or carriers were
acceptable excipient or carrier. comprises buffered physiological saline. specified
10. The composition of claim 1, in the 6. The composition of claim 1, in the form of a liquid, /
form of a liquid, semi-liquid, solid, or semi-liquid, solid, or lyophilized formulation.
lyophilized formulation.
11. The composition of claim 10, which 7. The composition of claim 6, which comprises between /
comprises between 10e4 and 10e12 PFU 10e4 and 10e12 PFU of each bacteriophage.
of each bacteriophage.
12. A method of treatment of an infection in 8. A method of treatment of an infection in a mammal in The phage composition amount
a mammal in need thereof comprising need thereof comprising contacting the mammal with and sequence identity were
contacting the mammal with a an effective amount of an antibacterial composition, specified
composition of claim 1. wherein said composition comprises at least one
bacteriophage having lytic activity against a
P. aeruginosa strain, said at least one bacteriophage
being selected from the bacteriophages having a
genome comprising any one of SEQ ID NOs: 2 – 7 or a
sequence having at least 99% identity thereto.
13. The method of claim 12, wherein 9. The method of claim 8, wherein the infection is an Unchanged
the infection is an infection of the infection of the respiratory tract.
respiratory tract.
14. A method for improving the condition 10. A method for improving the condition of a mammal The phage composition amount
of a mammal by modifying the by modifying the microbial flora in said mammal and sequence identity were
microbial flora in said mammal comprising contacting the mammal with an effective specified
comprising contacting the mammal with amount of an antibacterial composition, wherein said
a composition of claim 1. composition comprises at least one bacteriophage
having lytic activity against a P. aeruginosa strain, said
at least one bacteriophage being selected from the
bacteriophages having a genome comprising any one
of SEQ ID NOs: 2 – 7 or a sequence having at least
99% identity thereto.
(Cont’d...)

Volume 2 Issue 3 (2025) 69 doi: 10.36922/mi.4758